[go: up one dir, main page]

PL3618829T3 - Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem - Google Patents

Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem

Info

Publication number
PL3618829T3
PL3618829T3 PL18794742.9T PL18794742T PL3618829T3 PL 3618829 T3 PL3618829 T3 PL 3618829T3 PL 18794742 T PL18794742 T PL 18794742T PL 3618829 T3 PL3618829 T3 PL 3618829T3
Authority
PL
Poland
Prior art keywords
quinazoline
cancer
treatment
related disorders
pyridine derivatives
Prior art date
Application number
PL18794742.9T
Other languages
English (en)
Inventor
Manmohan Reddy Leleti
Dillon Harding MILES
Jay Patrick POWERS
Brandon Reid ROSEN
Ehesan Ul Sharif
Rhiannon THOMAS-TRAN
Original Assignee
Arcus Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences, Inc. filed Critical Arcus Biosciences, Inc.
Publication of PL3618829T3 publication Critical patent/PL3618829T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18794742.9T 2017-05-05 2018-05-03 Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem PL3618829T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502391P 2017-05-05 2017-05-05
US201862624273P 2018-01-31 2018-01-31
PCT/US2018/030909 WO2018204661A1 (en) 2017-05-05 2018-05-03 Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Publications (1)

Publication Number Publication Date
PL3618829T3 true PL3618829T3 (pl) 2023-11-20

Family

ID=64016681

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18794742.9T PL3618829T3 (pl) 2017-05-05 2018-05-03 Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem

Country Status (9)

Country Link
US (1) US11045472B2 (pl)
EP (1) EP3618829B1 (pl)
JP (1) JP7295034B2 (pl)
CN (1) CN110612100B (pl)
ES (1) ES2953349T3 (pl)
PL (1) PL3618829T3 (pl)
TW (1) TWI789393B (pl)
UY (1) UY37725A (pl)
WO (1) WO2018204661A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110636846B (zh) 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
CN109293586A (zh) * 2018-11-22 2019-02-01 云南师范大学 一种在氨水中微波条件下卤代苯甲酸合成喹唑啉酮化合物的方法
WO2020146563A1 (en) * 2019-01-10 2020-07-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers such as spp to increase tumor immunity and improve the efficacy of cancer immunotherapy
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
JP7474861B2 (ja) 2020-03-19 2024-04-25 アーカス バイオサイエンシーズ,インコーポレーテッド Hif-2アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
US11649261B2 (en) 2020-06-17 2023-05-16 Arcus Biosciences, Inc. Crystalline forms of a CD73 inhibitor and uses thereof
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
CN117337288A (zh) 2021-05-21 2024-01-02 艾库斯生物科学有限公司 Axl抑制剂化合物
US20240246967A1 (en) 2021-05-21 2024-07-25 Arcus Biosciences, Inc. Axl compounds
KR20240110814A (ko) 2021-10-29 2024-07-16 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 저해제 및 이의 사용 방법
EP4518895A1 (en) 2022-05-02 2025-03-12 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
US20240124490A1 (en) 2022-07-15 2024-04-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en) 2022-10-20 2024-04-25 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
US20240425497A1 (en) 2023-05-05 2024-12-26 Arcus Biosciences, Inc. Cbl-b Inhibitors and Methods of Use Thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1397364E (pt) * 2001-05-24 2007-10-22 Lilly Co Eli Novos derivados de pirrole como agentes farmacêuticos
TWI330183B (pl) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
AU2003249604B2 (en) * 2003-05-06 2011-06-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
JP2007514003A (ja) * 2003-12-15 2007-05-31 アルミラル プロデスファルマ アーゲー アデノシン受容体アンタゴニストとしての2,6−ビスヘテロアリール−4−アミノピリミジン
TW200813056A (en) * 2006-06-29 2008-03-16 King Pharmaceuticals Res Dev Inc Adenosine A2B receptor antagonists
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
WO2010033906A2 (en) * 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2016126570A1 (en) * 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist

Also Published As

Publication number Publication date
ES2953349T3 (es) 2023-11-10
EP3618829A4 (en) 2021-01-06
EP3618829B1 (en) 2023-06-07
EP3618829A1 (en) 2020-03-11
CN110612100B (zh) 2023-04-14
US20200069689A1 (en) 2020-03-05
UY37725A (es) 2018-10-31
JP2020518627A (ja) 2020-06-25
CN110612100A (zh) 2019-12-24
TW201843150A (zh) 2018-12-16
EP3618829C0 (en) 2023-06-07
US11045472B2 (en) 2021-06-29
JP7295034B2 (ja) 2023-06-20
TWI789393B (zh) 2023-01-11
WO2018204661A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
PL3618829T3 (pl) Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem
PL3634417T3 (pl) Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
IL271085A (en) Bacteria to treat disorders
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK1247129A1 (zh) 治療癌症的聯合療法
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
HK1251475A1 (zh) 用於癌症治療的聯合療法
IL259996A (en) Combinations for cancer treatment
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
IL267818A (en) Methods for treating neurological disorders
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
IL259674B (en) Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL273835A (en) Combined product for cancer treatment
EP3371154A4 (en) HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS
EP3507277B8 (en) Hydroxynorketamine derivatives for the treatment of disorders
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer
GB201602784D0 (en) New treatment of CFTR-related disorders